IP Library Assignment 040362/0884
Patent Assignment
Reel/Frame 040362/0884

Security Interest

Recorded: 2016-11-17 Pages: 11
Assignor
TOLERO PHARMACEUTICALS, INC.
Executed: 2016-11-02
Assignee
SUMITOMO DAINIPPON PHARMA CO., LTD.
6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA, 541-0045, JAPAN
Covered Properties (38)
Imidazo[1,2-Beta]Pyridazine and Pyrazolo[1,5-Alpha]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Patent: 7,750,007 →
Application: 11/935,959 →
Publication: US 2008/0261988
Pyrimidine-2,4-Diamine Derivatives and Their Use as JAK2 Kinase Inhibitors
Application: 12/040,002 →
Publication: US 2008/0214558
Axl Kinase Inhibitors
Patent: 7,998,966 →
Application: 12/101,591 →
Publication: US 2008/0293733
Methods and Compounds for Treating Pim-1 Kinase-Expressing Cancer Cells
Application: 12/785,322 →
Publication: US 2010/0227861
Axl Kinase Inhibitors
Application: 13/183,197 →
Publication: US 2011/0269772
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Patent: 8,710,057 →
Application: 13/188,195 →
Publication: US 2011/0281863
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES AS PROTEIN KINASE INHIBITORS
Patent: 9,416,132 →
Application: 14/234,109 →
Publication: US 2014/0329807
Multiple Kinase Pathway Inhibitors
Patent: 9,493,454 →
Application: 14/431,476 →
Publication: US 2015/0266870
PKM2 Modulators and Methods for Their Use
Patent: 9,394,257 →
Application: 14/435,976 →
Publication: US 2015/0344436
JAK2 and ALK2 Inhibitors and Methods for Their Use
Application: 14/776,392 →
Publication: US 2016/0214944
Predicting Response to Alvocidib by Mitochondrial Profiling
Patent: 9,901,574 →
Application: 15/134,051 →
Publication: US 2016/0303101
Alvocidib Prodrugs Having Increased Bioavailability
Patent: 9,758,539 →
Application: 15/158,206 →
Publication: US 2016/0340376
PKM2 Modulators and Methods for Their Use
Application: 15/183,581 →
Publication: US 2017/0015631
Substituted Imidazo[1,2-B]Pyridazines as Protein Kinase Inhibitors
Application: 15/207,224 →
Publication: US 2017/0002014
Multiple Kinase Pathway Inhibitors
Patent: 9,714,247 →
Application: 15/276,604 →
Publication: US 2017/0107215
IMIDAZO[1,2-b]PYRIDAZINE AND PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
Application: 60/864,566 →
Pyrimidine-2,4-Diamine Derivatives and Their Use as JAK2 Kinase Inhibitors
Application: 60/892,385 →
IMIDAZO[1,2-b]PYRIDAZINE AND PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
Application: 60/892,523 →
Pyrimidine-2,4-Diamine Derivatives and Their Use as JAK2 Kinase Inhibitors
Application: 60/911,776 →
Axl Kinase Inhibitors
Application: 60/911,832 →
IMIDAZO[1,2-b]PYRIDAZINE AND PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS
Application: 60/957,988 →
[1,2,4]Triazolo[4,3-A]Pyridine Derivatives and Their Use as Protein Kinase Inhibitors
Application: 61/510,207 →
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Application: 61/608,028 →
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Application: 61/632,826 →
Imidazo[1,2-B]Pyridazine and Pyrazolo[1,5-a]Pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors
Application: 61/632,834 →
Publication: US 2012/0058997
Multiple Kinase Pathway Inhibitors
Application: 61/706,084 →
PKM2 Modulators and Methods for Their Use
Application: 61/714,659 →
Multiple Kinase Pathway Inhibitors
Application: 61/757,331 →
JAK2 and ALK2 Inhibitors and Methods for Their Use
Application: 61/785,460 →
Multiple Kinase Pathway Inhibitors
Application: 61/785,992 →
PKM2 Modulators and Methods for Their Use
Application: 61/875,855 →
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 62/077,042 →
Targeting the Pim Kinases in Combination with Btk Inhibition Is Synergistic in Preclinical Models of B-Cell Malignancies
Application: 62/142,354 →
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 62/150,110 →
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 62/150,138 →
Targeting Pim Kinases in Combination with Btk Inhibition
Application: 62/150,695 →
Alvocidib Prodrugs Having Increased Bioavailability
Application: 62/163,188 →
Combination Therapies for Treatment of Cancer
Application: 62/200,499 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Mar 2, 2007
From: BEARSS, DAVID J.; VANKAYALAPATI, HARIPRASAD; LIU, XIAO-HUI
To: SUPERGEN, INC.
Reel/Frame 018954/0792 →
Assignment of Assignor's Interest Mar 30, 2007
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD
To: SUPERGEN, INC.
Reel/Frame 019095/0209 →
Assignment of Assignor's Interest Apr 17, 2007
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD
To: SUPERGEN, INC.
Reel/Frame 019169/0031 →
Assignment of Assignor's Interest Apr 25, 2007
From: BEARSS, DAVID J.; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: SUPERGEN, INC.
Reel/Frame 019211/0413 →
Assignment of Assignor's Interest Nov 8, 2007
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD
To: SUPERGEN, INC.
Reel/Frame 020085/0921 →
Assignment of Assignor's Interest Mar 13, 2008
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD
To: SUPERGEN, INC.
Reel/Frame 020648/0486 →
Assignment of Assignor's Interest Mar 28, 2008
From: BEARSS, DAVID J.; LIU, XIAO-HUI; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: SUPERGEN, INC.
Reel/Frame 020721/0348 →
Assignment of Assignor's Interest May 8, 2008
From: VANKAYALAPATI, HARIPRASAD; LIU, XIAO-HUI; BEARSS, DAVID J.
To: SUPERGEN, INC.
Reel/Frame 020918/0017 →
Assignment of Assignor's Interest Jul 29, 2008
From: BEARSS, DAVID J.; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: SUPERGEN, INC.
Reel/Frame 021309/0536 →
Assignment of Assignor's Interest Nov 15, 2011
From: XU, YONG; YUAN, YI; BRENNING, BENJAMIN G.; HO, KOC-KAN
To: SUPERGEN, INC.
Reel/Frame 027230/0779 →
Merger/Name Change Feb 22, 2012
From: SUPERGEN, INC.
To: ASTEX PHARMACEUTICALS. INC.
Reel/Frame 027747/0334 →
Assignment of Assignor's Interest Jul 26, 2012
From: ASTEX PHARMACEUTICALS, INC.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 028650/0717 →
Assignment of Assignor's Interest Aug 12, 2014
From: XU, YONG; BRENNING, BENJAMIN GARY; KULTGEN, STEVEN G.; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 033521/0153 →
Assignment of Assignor's Interest Aug 10, 2015
From: MOLLARD, ALEXIS; WARNER, STEVEN L.; FLYNN, GARY A.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 036291/0103 →
Assignment of Assignor's Interest Aug 10, 2015
From: ZENG, QINGPING; FARIS, MARY
To: MANNKIND CORPORATION
Reel/Frame 036291/0088 →
Assignment of Assignor's Interest Nov 10, 2015
From: HO, KOC-KAN; XU, YONG; SAUNDERS, MICHAEL DAVID; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 037005/0571 →
Assignment of Assignor's Interest Mar 22, 2016
From: MOLLARD, ALEXIS; WARNER, STEVEN L.; FLYNN, GARY A.; VANKAYALAPATI, HARIPRASAD
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 038068/0314 →
Assignment of Assignor's Interest Aug 5, 2016
From: SIDDIQUI-JAIN, ADAM; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 039358/0432 →
Assignment of Assignor's Interest Aug 31, 2016
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 039601/0719 →
Assignment of Assignor's Interest Dec 19, 2018
From: HO, KOC-KAN; XU, YONG; SAUNDERS, MICHAEL DAVID; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 047959/0693 →
Release of Security Interest Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
Security Interest Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
Assignment of Assignor's Interest Apr 27, 2020
From: XU, YONG; BRENNING, BENJAMIN GARY; KULTGEN, STEVEN G.; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 052500/0211 →
Merger Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053181/0114 →
Merger Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053172/0344 →